Zynlonta

Zynlonta (loncastuximab tesirine) is an intravenous therapy for relapsed or refractory large B-cell lymphoma. This targeted antibody-drug conjugate is designed to treat specific blood cancers. Always consult a healthcare provider for personalized guidance.

Zynlonta is used to treat relapsed or refractory large B-cell lymphoma, a type of blood cancer. It is prescribed when other treatments have not been effective. Patients often seek options like Zynlonta after standard therapies fail to control the disease. This medication targets cancer cells directly.

Zynlonta works by delivering a chemotherapy agent directly to cancer cells, which may help reduce tumor size. Patients may experience changes in blood cell counts during treatment. Regular monitoring is typically required to assess response and manage potential effects.

Zynlonta is administered by healthcare professionals in a controlled setting. Patients should report any signs of infection, fatigue, or unusual symptoms immediately. Blood tests are commonly used to track progress and adjust care as needed.

Zynlonta may interact with other medications, including strong CYP3A inhibitors or inducers. Patients should inform their doctor about all drugs, supplements, or herbal products they are using. Avoiding alcohol and certain foods may be recommended during treatment.